vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2018-4-100-106vtio-956Research ArticleОбзор литературыLiterature ReviewsВысокая проницаемость мембран для гемодиализа: плюсы и минусыHigh dialysis membranes permeability: pluses and minusesСтроковА. Г.StrokovA. G.

Москва

Moscow

ПозЯ. Л.PozI. L.

123182, Москва, ул. Щукинская, д. 1Тел. (916) 606-77-16

1, Shchukinskaya str., Moscow, 123182Tel. (916) 606-77-16

dr.poz@list.ruФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationRussian Federation201831012019204100106Copyright © Строков А.Г., Поз Я.Л., 20192019Строков А.Г., Поз Я.Л.Strokov A.G., Poz I.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/956

Современные технологии производства мембран для гемодиализа позволили существенно повысить их биосовместимость и проницаемость. Новые разновидности мембран – с высокой и средней точками отсечения по молекулярной массе просеивающихся веществ – позволяют эффективно удалять не только средние молекулы, такие как β2 -микроглобулин, но и более размерные молекулы. Высокая проницаемость современных диализных мембран и широкое внедрение конвективных методик сопряжены с повышенной потерей альбумина в ходе сеансов лечения. Какой уровень таких потерь можно считать приемлемым и где находится точка равновесия между преимуществами повышенного выведения уремических соединений и потенциальной опасностью избыточного просеивания альбумина – эти вопросы требуют дальнейших исследований.

Up-to-date technologies have led to significant improvement of haemodialysis membranes biocompatibility and permeability. The new classes of membranes, high cut-off and middle cut-off, allow enhanced removal of middle molecules such as β2-microglobulin and even larger molecules. High membrane permeability along with the wide use of convective modalities are accompanied by increased albumin loss during dialysis. What is the acceptable upper limit for this loss and where is the right balance between the benefit of enhanced uremic substances removal and potential adverse effects of albumin deprivation are the active areas of research.

гемодиализмембраныпроницаемость мембранмембраны со средней точкой отсеченияпотери альбуминаhaemodialysismembranemembrane permeabilitymiddle cut­offalbumin lossReferencesKolff W, Berk H. The artificial kidney: a dialyzer with a great area. Acta Med Scand. 1944; 117: 121–134. PMID: 9402100.Kolff W, Berk H. The artificial kidney: a dialyzer with a great area. Acta Med Scand. 1944; 117: 121–134. PMID: 9402100.Kiil F. Development of a parallel-flow artificial kidney in plastics. Acta Chir Scand. 1960; Suppl 253: 142–150. PMID: 14409028.Kiil F. Development of a parallel-flow artificial kidney in plastics. Acta Chir Scand. 1960; Suppl 253: 142–150. PMID: 14409028.Lipps BJ, Stewart RD, Perkins HA, Holmes GW, McLain EA, Rolfs MR, Oja PD. The hollow fiber artificial kidney. Trans Am Soc Artif Intern Organs. 1967; 13: 200–207.Lipps BJ, Stewart RD, Perkins HA, Holmes GW, McLain EA, Rolfs MR, Oja PD. The hollow fiber artificial kidney. Trans Am Soc Artif Intern Organs. 1967; 13: 200–207.Hakim RM.Clinical implications of hemodialysis membrane bioincompatibility. Kidney Int.1993; 44: 484–494. PMID: 8231020.Hakim RM.Clinical implications of hemodialysis membrane bioincompatibility. Kidney Int.1993; 44: 484–494. PMID: 8231020.Clark WR, Gao D, Ronco C. Membranes for dialysis: composition, structure, and function. Contrib Nephrol. 2002; 137: 70–77. PMID: 12101993.Clark WR, Gao D, Ronco C. Membranes for dialysis: composition, structure, and function. Contrib Nephrol. 2002; 137: 70–77. PMID: 12101993.Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006; 17 (2): 546–555. doi: 10.1681/ASN.2005020132.Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006; 17 (2): 546–555. doi: 10.1681/ASN.2005020132.Okuno S, Ishimura E, Kohno K, Fujino­Katoh Y, Maeno Y, Yamakawa T et al. Serum β2 -microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant. 2009; 24: 571–577. doi: 10.1093/ndt/gfn521.Okuno S, Ishimura E, Kohno K, Fujino­Katoh Y, Maeno Y, Yamakawa T et al. Serum β2 -microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant. 2009; 24: 571–577. doi: 10.1093/ndt/gfn521.European Best Practice Guidelines for Haemodialysis II. 2 Haemodialysis dose quantification: middle molecules. Nephrol Dial Transplant. 2002; 17, Suppl. 7: 21–23. doi: 10.1093/ndt/17.suppl_7.21.European Best Practice Guidelines for Haemodialysis II. 2 Haemodialysis dose quantification: middle molecules. Nephrol Dial Transplant. 2002; 17, Suppl. 7: 21–23. doi: 10.1093/ndt/17.suppl_7.21.Roumelioti M­E, Trietley G, Nolin TD, Ng Y­H, Xu Z, Alaini A et al. Beta-2 microglobulin clearance in highflux dialysis and convective dialysis modalities: a metaanalysis of published studies. Nephrol Dial Transplant. 2018; 33: 1025–1039. doi: 10.1093/ndt/gfx311.Roumelioti M­E, Trietley G, Nolin TD, Ng Y­H, Xu Z, Alaini A et al. Beta-2 microglobulin clearance in highflux dialysis and convective dialysis modalities: a metaanalysis of published studies. Nephrol Dial Transplant. 2018; 33: 1025–1039. doi: 10.1093/ndt/gfx311.Campistol JM., Torregrosa JV, Ponz E, Fenollosa B. β2 -microglobulin removal by hemodialysis polymethylmetacrylate membranes. Contrib Nephrol. 1998; 125: 76–85. PMID: 9895432.Campistol JM., Torregrosa JV, Ponz E, Fenollosa B. β2 -microglobulin removal by hemodialysis polymethylmetacrylate membranes. Contrib Nephrol. 1998; 125: 76–85. PMID: 9895432.Tattersall JE, Ward RA.EUDIAL group. Online hemodiafiltration: definition, dose quantification, and safety revisited. Nephrol Dial Transplant.2013; 28: 542–550. doi: 10.1093/ndt/gfs530.Tattersall JE, Ward RA.EUDIAL group. Online hemodiafiltration: definition, dose quantification, and safety revisited. Nephrol Dial Transplant.2013; 28: 542–550. doi: 10.1093/ndt/gfs530.Wizemann V, Lotz C, Techert F, Utholff S. On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. Nephrol Dial Transplant. 2000; 15: 43–48. PMID: 10737166.Wizemann V, Lotz C, Techert F, Utholff S. On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. Nephrol Dial Transplant. 2000; 15: 43–48. PMID: 10737166.Canaud B, Barbieri C, Marcelli D, Bellocchio F, Bowry S, Mari F et al. Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration. Kidney Int. 2015; 88 (5): 1108–1116. doi: 10.1038/ki.2015.139.Canaud B, Barbieri C, Marcelli D, Bellocchio F, Bowry S, Mari F et al. Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration. Kidney Int. 2015; 88 (5): 1108–1116. doi: 10.1038/ki.2015.139.Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G. An update on uremic toxins. Int Urol Nephrol.2013; 45: 139–150. doi: 10.1007/s11255-012-0258-1.Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G. An update on uremic toxins. Int Urol Nephrol.2013; 45: 139–150. doi: 10.1007/s11255-012-0258-1.Boschetti­de­Fierro A, Voigt M, Storr M, Krause B. Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. Int J Artif Organs. 2013; 36: 455–463. doi: 10.5301/ijao.5000220.Boschetti­de­Fierro A, Voigt M, Storr M, Krause B. Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. Int J Artif Organs. 2013; 36: 455–463. doi: 10.5301/ijao.5000220.Boschetti­de­Fierro A, Voigt M, Storr M, Krause B. MCO Membranes: Enhanced Selectivity in High-Flux Class. Sci Rep. 2015; 5: 18448. doi: 10.1038/srep18448.Boschetti­de­Fierro A, Voigt M, Storr M, Krause B. MCO Membranes: Enhanced Selectivity in High-Flux Class. Sci Rep. 2015; 5: 18448. doi: 10.1038/srep18448.Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017; 32 (1): 165–172. doi: 10.1093/ndt/gfw310.Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017; 32 (1): 165–172. doi: 10.1093/ndt/gfw310.Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M et al. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients – A Randomized Controlled Clinical Trial. PLoS One. 2017 Jan 13; 12 (1): e0169024. doi: 10.1371/journal.pone.0169024.Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M et al. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients – A Randomized Controlled Clinical Trial. PLoS One. 2017 Jan 13; 12 (1): e0169024. doi: 10.1371/journal.pone.0169024.Fiore GB, Guadagni G, Lupi A, Ricci Z, Ronco C. A new semiempirical mathematical model for prediction of internal filtration in hollow fiber hemodialyzers. Blood Purif. 2006; 24: 555–568 doi: 10.1159/000097079.Fiore GB, Guadagni G, Lupi A, Ricci Z, Ronco C. A new semiempirical mathematical model for prediction of internal filtration in hollow fiber hemodialyzers. Blood Purif. 2006; 24: 555–568 doi: 10.1159/000097079.Ronco C. The Rise of Expanded Hemodialysis. Blood Purif. 2017; 44: I–VIII. doi: 10.1159/000476012.Ronco C. The Rise of Expanded Hemodialysis. Blood Purif. 2017; 44: I–VIII. doi: 10.1159/000476012.Maduell F, Moreso F, Pons M, Ramos R, Mora­Macià J, Carreras J et al. ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013; 24: 487–497. doi: 10.1681/ASN.2012080875.Maduell F, Moreso F, Pons M, Ramos R, Mora­Macià J, Carreras J et al. ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013; 24: 487–497. doi: 10.1681/ASN.2012080875.Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int. 1994; 46: 830–837. PMID: 7996804.Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int. 1994; 46: 830–837. PMID: 7996804.Kaysen GA, Dubin JA, Müller HG, Mitch WE, Rosales LM, Levin NW. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int. 2002; 61: 2240–2249. doi: 10.1046/j.1523-1755.2002.00076.x.Kaysen GA, Dubin JA, Müller HG, Mitch WE, Rosales LM, Levin NW. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int. 2002; 61: 2240–2249. doi: 10.1046/j.1523-1755.2002.00076.x.Kneis C, Beck W, Boenisch O, Klefisch F, Deppisch R, Zickler D et al. Elimination of middle-sized uremic solutes with high-flux and high-cut-off membranes: A randomized in vivostudy. Blood Purif. 2014; 36: 287–294. doi: 10.1159/000356224.Kneis C, Beck W, Boenisch O, Klefisch F, Deppisch R, Zickler D et al. Elimination of middle-sized uremic solutes with high-flux and high-cut-off membranes: A randomized in vivostudy. Blood Purif. 2014; 36: 287–294. doi: 10.1159/000356224.Tsuchida K, Minakuchi J.Albumin loss under the use of the high-performance membrane. Contrib Nephrol. 2011; 173: 76–83. doi: 10.1159/000328957.Tsuchida K, Minakuchi J.Albumin loss under the use of the high-performance membrane. Contrib Nephrol. 2011; 173: 76–83. doi: 10.1159/000328957.Fiedler R, Neugebauer F, Ulrich C, Wienke A, Gromann C, Storr M et al. Randomized controlled pilot study of 2 weeks’ treatment with high cutoff membrane for hemodialysis patients with elevated c-reactive protein. Artif Organs. 2012; 36: 886–893. doi: 10.1111/j.1525-1594.2012.01479.x.Fiedler R, Neugebauer F, Ulrich C, Wienke A, Gromann C, Storr M et al. Randomized controlled pilot study of 2 weeks’ treatment with high cutoff membrane for hemodialysis patients with elevated c-reactive protein. Artif Organs. 2012; 36: 886–893. doi: 10.1111/j.1525-1594.2012.01479.x.Nagai K, Tsuchida K, Ishihara N, Naoto Minagawa N, Ichien G, Yamada S et al. Implications of albumin leakage for survival in maintenance hemodialysis patients: a 7-year observational study. Ther Apher Dial. 2017; 21: 378–386. doi: 10.1111/1744-9987.12526.Nagai K, Tsuchida K, Ishihara N, Naoto Minagawa N, Ichien G, Yamada S et al. Implications of albumin leakage for survival in maintenance hemodialysis patients: a 7-year observational study. Ther Apher Dial. 2017; 21: 378–386. doi: 10.1111/1744-9987.12526.Ahrenholz PG, Winkler RE, Michelsen A, Lang DA, Bowry SK. Dialysis membrane-dependent removal of middle molecules during hemodiafiltration: the beta2-microglobulin/ albumin relationship. Clin Nephrol. 2004; 62: 21–28. PMID: 15267009.Ahrenholz PG, Winkler RE, Michelsen A, Lang DA, Bowry SK. Dialysis membrane-dependent removal of middle molecules during hemodiafiltration: the beta2-microglobulin/ albumin relationship. Clin Nephrol. 2004; 62: 21–28. PMID: 15267009.Maduell F, Arias­Guillen M, Fontseré N, Ojeda R, Rico N, Vera M et al. Elimination of large uremic toxins by a dialyzer specifically designed for high-volume convective therapies. Blood Purif. 2014; 37: 125–130. doi: 10.1159/000358214.Maduell F, Arias­Guillen M, Fontseré N, Ojeda R, Rico N, Vera M et al. Elimination of large uremic toxins by a dialyzer specifically designed for high-volume convective therapies. Blood Purif. 2014; 37: 125–130. doi: 10.1159/000358214.Fournier A, Birmele B, Francois M, Prat L, Halimi JM. Factors associated with albumin loss in post-dilution hemodiafiltration. Int J Artif Organs. 2015; 38: 76–82. doi: 10.5301/ijao.5000389.Fournier A, Birmele B, Francois M, Prat L, Halimi JM. Factors associated with albumin loss in post-dilution hemodiafiltration. Int J Artif Organs. 2015; 38: 76–82. doi: 10.5301/ijao.5000389.Vega A, Quiroga B, Abad S, Aragoncillo I, Arroyo D, Panizo N et al. Albumin leakage in online hemodiafiltration, more convective transport, more losses? Ther Apher Dial. 2015; 19: 267–271. doi: 10.1111/1744-9987.12247.Vega A, Quiroga B, Abad S, Aragoncillo I, Arroyo D, Panizo N et al. Albumin leakage in online hemodiafiltration, more convective transport, more losses? Ther Apher Dial. 2015; 19: 267–271. doi: 10.1111/1744-9987.12247.Gayrard N, Ficheux A, Duranton F, Guzman C, Szwarc I, Vetromile F et al. Correction: Consequences of increasing convection onto patient care and protein removal in hemodialysis. PLoS One. 2018; 13 (1): e0190761. doi: 10.1371/journal.pone.0190761.Gayrard N, Ficheux A, Duranton F, Guzman C, Szwarc I, Vetromile F et al. Correction: Consequences of increasing convection onto patient care and protein removal in hemodialysis. PLoS One. 2018; 13 (1): e0190761. doi: 10.1371/journal.pone.0190761.Yamashita AC, Sakurai K. Clinical effect of pre-dilution hemodiafiltration based on the permeation of the hemodiafilter. Contrib Nephrol. 2015; 185: 1–7. doi: 10.1159/000380964.Yamashita AC, Sakurai K. Clinical effect of pre-dilution hemodiafiltration based on the permeation of the hemodiafilter. Contrib Nephrol. 2015; 185: 1–7. doi: 10.1159/000380964.Potier J, Le Roy F, Faucon JP, Besselièvre T, Renaudineau E, Farquet C et al. Elevated removal of middle molecules without significant albumin loss with mixeddilution hemodiafiltration for patients unable to provide sufficient blood flow rates. Blood Purif. 2013; 36: 78–83. doi: 10.1159/000351527.Potier J, Le Roy F, Faucon JP, Besselièvre T, Renaudineau E, Farquet C et al. Elevated removal of middle molecules without significant albumin loss with mixeddilution hemodiafiltration for patients unable to provide sufficient blood flow rates. Blood Purif. 2013; 36: 78–83. doi: 10.1159/000351527.Kim ST, Yamamoto C, Taoka M, Takasugi M. Programmed filtration, a new method for removing large molecules and regulating albumin leakage during hemodiafiltration treatment. Am J Kidney Dis. 2001; 38: S220–S223. PMID: 11576960.Kim ST, Yamamoto C, Taoka M, Takasugi M. Programmed filtration, a new method for removing large molecules and regulating albumin leakage during hemodiafiltration treatment. Am J Kidney Dis. 2001; 38: S220–S223. PMID: 11576960.Pedrini LA, Cozzi G, Faranna P, Mercieri A, Ruggiero P, Zerbi S et al. Transmembrane pressure modulation in high-volume mixed hemodiafiltration to optimize efficiency and minimize protein loss. Kidney Int. 2006; 69: 573–579. doi: 10.1038/sj.ki.5000110.Pedrini LA, Cozzi G, Faranna P, Mercieri A, Ruggiero P, Zerbi S et al. Transmembrane pressure modulation in high-volume mixed hemodiafiltration to optimize efficiency and minimize protein loss. Kidney Int. 2006; 69: 573–579. doi: 10.1038/sj.ki.5000110.

The authors declare that there are no conflicts of interest present.